Search
for

    Glossary Alfuzosin

    Alfuzosin is a medication primarily used to treat benign prostatic hyperplasia (BPH) by relaxing the muscles in the prostate and bladder neck, which helps improve urine flow. Its relevance to hair loss lies in its potential side effects, as some studies suggest that alpha-1 adrenergic antagonists like alfuzosin may influence hair growth patterns. Key distinguishing characteristics include its mechanism of action as an alpha-blocker and its specific use in managing urinary symptoms associated with prostate enlargement, rather than directly addressing hair loss conditions.

    Sort by

    Research 30 of 103

    1. Rapid and Sensitive LC–MS–MS Method for the Simultaneous Estimation of Alfuzosin and Dutasteride in Human Plasma Chromatographia · 2008 · 25 citations
    2. Reversible visual loss caused by combination therapy of alfuzosin and finasteride in a patient with uveitic glaucoma Cutaneous and Ocular Toxicology · 2012 · 2 citations
    3. Alfuzosin/finasteride Reactions Weekly · 2023
    4. Alfuzosin/finasteride Reactions Weekly · 2013
    5. Validated HPTLC method for the simultaneous determination of alfuzosin, terazosin, prazosin, doxazosin and finasteride in pharmaceutical formulations Analytical Chemistry Research · 2014 · 26 citations
    6. A Comparison of Varying alpha-Blockers and Other Pharmacotherapy Options for Lower Urinary Tract Symptoms. PubMed · 2005 · 52 citations
    7. Risk factors for intraoperative floppy iris syndrome: a retrospective study Acta Ophthalmologica · 2011 · 22 citations
    8. Medikamentöse Therapie des benignen Prostatasyndroms Der Urologe · 2015 · 20 citations
    9. Editorial Comment Urology · 2008 · 1 citations
    10. Is sulfonamide group of tamsulosin main factor in the pathophysiology of floppy iris syndrome? Haydarpaşa Numune Hastanesi tıp dergisi · 2018
    11. Medikamentöse Therapie des benignen Prostatasyndroms (BPS) Aktuelle Urologie · 2006
    12. Medikamentöse Therapie des benignen Prostatasyndroms mit α1-Rezeptorblockern Grundlagen und klinische Ergebnisse Der Urologe · 2002 · 22 citations
    13. Medical Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia European urology. Supplement · 2009 · 10 citations
    14. The role of benign prostatic hyperplasia treatments in ejaculatory dysfunction Fertility and Sterility · 2021 · 8 citations
    15. Key Clinical Trials in BPH 2002 · 4 citations
    16. Floppy Iris Syndrome Essentials in ophthalmology · 2022
    17. Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS) Figshare · 2026
    18. Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS) Figshare · 2026
    19. Risk factors for intraoperative floppy iris syndrome: One year prospective study Acta Ophthalmologica · 2013
    20. Effects of <i>In Utero</i> Exposure to D-004, a Lipid Extract from <i>Roystonea regia</i> Fruits, in the Male Rat: A Comparison with Finasteride Journal of Medicinal Food · 2011 · 8 citations
    21. Do Alpha-Blockers and 5-Alpha Reductase Inhibitors Increase Dementia Risk? A Network Meta-analysis International Neurourology Journal · 2025
    22. A Case of Gynecomastia Induced by Use of Doxazosin Korean Journal of Medicine · 2016
    23. The role of dutasteride in the treatment of benign prostatic obstruction and related conditions Aging Health · 2006
    24. Epidemiology and treatment modalities for the management of benign prostatic hyperplasia Translational Andrology and Urology · 2019 · 110 citations
    25. Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician BJU international · 2004 · 98 citations
    26. Finasteride Drugs · 1993 · 86 citations
    27. Adverse effects of common medications on male fertility Nature Reviews Urology · 2015 · 77 citations
    28. What do we know about phytotherapy of benign prostatic hyperplasia? Life Sciences · 2015 · 67 citations
    29. Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases The Journal of Steroid Biochemistry and Molecular Biology · 2013 · 51 citations
    30. Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial British Journal of Cancer · 2009 · 49 citations